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The Raﬄ  es Dialogue on 
Human Wellbeing and 
Security
In The Lancet Global Health (August, 
2015),1 Tikki Pang and colleagues 
emphasise that “we must find the 
right balance between the roles of 
government and markets so that all 
those in need can access affordable 
medicine and health care“.1 Probably 
the biggest imbalance between role 
of government and market is in drug 
discovery and development. There 
is almost no way to finance large 
clinical trials of old, unpatentable 
drugs repurposed for treatment 
of deadly diseases. It has been the 
case for phase 3 clinical trials of 
paromomycin, an old antibiotic for 
visceral leishmaniasis, which were 
funded by the Bill & Melinda Gates 
Foundation, the WHO, and other 
institutions, but not by governments.2 
At the same time, such clinical trials 
may lead to very eﬃ  cient and low-cost 
drugs developed in the public interest. 
The cost of paromomycin is €4·19 for 
a 21 day course for a 35 kg patient.3 
Recently, The Oncologist published 
results of a clinical trial of an old drug 
used in alcohol-aversion therapy, 
disulﬁ ram, in patients with metastatic 
lung cancer.4 The drug is unpatentable, 
inexpensive, and widely affordable, 
but there is no financial interest in 
its further clinical development. The 
governments, especially those of 
rich countries, should systematically 
monitor positive side-effects of 
existing drugs and invest in their clinical 
development as non-proﬁ t drugs.5  
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